Detailed view for LmjF.24.1770

Basic information

TDR Targets ID: 21853
Leishmania major, inhibitor of cysteine peptidase
Source Database / ID:  TriTrypDB  GeneDB

pI: 9.3804 | Length (AA): 117 | MW (Da): 12979 | Paralog Number: 0

Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0

Druggability Group : DG1

Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable

Pfam domains

PF09394   Chagasin family peptidase inhibitor I42

Gene Ontology

Mouse over links to read term descriptions.
No GO information for this protein.

Metabolic Pathways

This gene is not mapped to any metabolic pathway in KEGG.

Structural information

Modbase 3D models:

There are 2 models calculated for this protein. More info on these models, including the models themselves is available at: Modbase

Target Beg Target End Template Template Beg Template End Identity Evalue Model Score MPQS zDope
5 117 2c34 (A) 1 113 67.00 0 1 1.74 -0.28
5 117 2c34 (A) 1 113 67.00 0 1 1.78401 -0.54

Help me make sense of these data.

Target Beg: first modeled residue
Target End: last modeled residue
Template: template structure used for modelling (PDB accession and chain)
Template Beg: first template residue in target-template alignment
Template End: last template residue in target-template alignment
Identity: sequence identity
Evalue: E value for target-template hit
Model Score: GA341 score (>0.7 for reliable model)
MPQS: ModPipe Quality Score (>1.1 for reliable model)
zDope: zDope Score (negative for reliable model)

A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.

PDB Structures:

PDB tag
  • 2C34:
  • Resolution Method # Atoms # Residues Dep. Date Pub. Date Mod. Date

Expression

Upregulation Percent Ranking Stage Dataset
Upper 80-100% percentile amastigotes, metacyclic. Fernandes MC
Show/Hide expression data references
  • Fernandes MC Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures.

Orthologs

Ortholog group members (OG5_136685)

Species Accession Gene Product
Cryptosporidium hominis Chro.60226   transmembrane protein
Cryptosporidium parvum cgd6_1910   conserved hypothetical protein
Entamoeba histolytica EHI_159600   cysteine protease inhibitor 1 (EhICP1)
Entamoeba histolytica EHI_040460   cysteine protease inhibitor 2 (EhICP2)
Leishmania braziliensis LbrM.24.1840   inhibitor of cysteine peptidase
Leishmania donovani LdBPK_241840.1   inhibitor of cysteine peptidase
Leishmania infantum LinJ.24.1840   inhibitor of cysteine peptidase
Leishmania major LmjF.24.1770   inhibitor of cysteine peptidase
Leishmania mexicana LmxM.24.1770   inhibitor of cysteine peptidase
Trypanosoma brucei gambiense Tbg972.8.6530   inhibitor of cysteine peptidase, putative,ICP, putative
Trypanosoma brucei Tb927.8.6450   inhibitor of cysteine peptidase
Trypanosoma cruzi TcCLB.506801.80   cysteine peptidase inhibitor
Trypanosoma cruzi TcCLB.511907.200   cysteine peptidase inhibitor, putative

Essentiality

LmjF.24.1770 has one or more orthologs with essentiality data
Gene/Ortholog Organism Phenotype Source Study
Tb927.8.6450 Trypanosoma brucei no significant loss or gain of fitness in bloodstream forms (3 days) alsford
Tb927.8.6450 Trypanosoma brucei no significant loss or gain of fitness in bloodstream forms (6 days) alsford
Tb927.8.6450 Trypanosoma brucei significant loss of fitness in procyclic forms alsford
Tb927.8.6450 Trypanosoma brucei no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms alsford
Show/Hide essentiality data references
  • gerdes Experimental determination and system-level analysis of essential genes in E. coli MG1655 Gerdes et al., J Bacteriol. 2003 185:5673-84
  • nmpdr Genome-scale essentiality datasets from published studies (M. tuberculosis) National Microbial Pathogen Data Resource
  • alsford High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome Genome Res 2011, 21:915-924
  • plasmo Functional Profiling of a Plasmodium Genome Reveals an Abundance of Essential Genes. Bushell, Ellen, et al. "Functional profiling of a Plasmodium genome reveals an abundance of essential genes." Cell 170.2 (2017): 260-272.
  • blattner Systematic mutagenesis of the E. coli (MG1655) genome J Bacteriol 2004, 186:4921-4930
  • keio Systematic single-gene knock-out mutants of E. coli K12 The Keio Collection
  • neb C. elegans RNAi phenotypes Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs
  • goodall The Essential Genome of Escherichia coli K-12 (Transposon directed high-throughput mutagenesis) Goodall, Emily CA, et al. "The essential genome of Escherichia coli K-12." mBio 9.1 (2018): e02096-17.
  • sidik A Genome-wide CRISPR Screen in Toxoplasma Identifies Essential Apicomplexan Genes. Sidik, Saima M., et al. "A genome-wide CRISPR screen in toxoplasma identifies essential apicomplexan genes." Cell 166.6 (2016): 1423-1435.
  • shigen Profiling of E. coli Chromosome (PEC) National Institute of Genetics, Japan
  • wormbase C. elegans RNAi experiments WormBase web site, http://www.wormbase.org, release WS170
  • yeastgenome Systematic deletion of yeast genes Saccharomyces Genome Database

Phenotypes and Validation (curated)

Annotated phenotypes:

Affected Entity Phenotypic quality Occurs in Occurs at Evidence Observed in Drugs/Inhibitors
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from bioassay (ECO:0000094) Leishmania mexicana 337527   561727   585910  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 4174-73-6. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in cell assay; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 7179420
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania mexicana 337527   561727   585910  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 4174-73-6. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in cell assay; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 7179420
catalytic activity (GO:0003824) decreased (PATO:0000468) in vitro (MI:0492) inferred from enzyme assay (ECO:0000005) Leishmania mexicana 337527   561727   585910  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 4174-73-6. chemical inhibition with known cysteine peptidase inhibitors leads to reduced enzyme activity in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 7179420
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from bioassay (ECO:0000094) Leishmania amazonensis No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: L-Amino acid esters appear to be hydrolyzed by cysteine peptidase and lead to slow growth of Leishmania sp. in cell assay; . References: 1428504 2235078 2345655
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from bioassay (ECO:0000094) Leishmania mexicana No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in cell assay; . References: 2270108
catalytic activity (GO:0003824) decreased (PATO:0000468) in vitro (MI:0492) inferred from enzyme assay (ECO:0000005) Leishmania amazonensis 81384   576750  
Annotator: aaronjr@u.washington.edu. Comment: chemical inhibition with known cysteine peptidase inhibitors leads to reduced enzyme activity in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 8023752
catalytic activity (GO:0003824) decreased (PATO:0000468) in vitro (MI:0492) inferred from enzyme assay (ECO:0000005) Leishmania major 81384   576750  
Annotator: aaronjr@u.washington.edu. Comment: chemical inhibition with known cysteine peptidase inhibitors leads to reduced enzyme activity in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 8023752
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) host (GO:0018995) Leishmania donovani No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 81989-95-9. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse) and cure of parasite burden; also provided protection against further infection (partial vaccine); General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 11238649
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from bioassay (ECO:0000094) Leishmania donovani No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 81989-95-9. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse) and cure of parasite burden; also provided protection against further infection (partial vaccine); General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 11238649
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) host (GO:0018995) Leishmania tropica No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 233277-99-1. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse lesions) and reduced lesion size; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 15172223
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from bioassay (ECO:0000094) Leishmania tropica No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 233277-99-1. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse lesions) and reduced lesion size; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 15172223
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania tropica No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 233277-99-1. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in cell assay; inhibitors overcome redundancy?; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 15172223
viability (PATO:0000169) decreased (PATO:0000468) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from bioassay (ECO:0000094) Leishmania mexicana No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: ICP null mutant generated without affecting growth or differentiation, but reducing infectivity in vivo (balb/c mouse); Q868H1_LEIME; . References: 15554964 16407198 16596344
viability (PATO:0000169) decreased (PATO:0000468) single cell organism (CARO:0000064) amastigote (BTO:0000062) host (GO:0018995) Leishmania mexicana No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: ICP null mutant generated without affecting growth or differentiation, but reducing infectivity in vivo (balb/c mouse); Q868H1_LEIME; . References: 15554964 16407198 16596344
viability (PATO:0000169) decreased (PATO:0000468) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from loss-of-function mutant phenotype (ECO:0000016) Leishmania mexicana No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: ICP null mutant generated without affecting growth or differentiation, but reducing infectivity in vivo (balb/c mouse); Q868H1_LEIME; . References: 15554964 16407198 16596344
viability (PATO:0000169) decreased (PATO:0000468) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from bioassay (ECO:0000094) Leishmania mexicana No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: overexpression of ICP generated without affecting growth or differentiation, but reducing virulence in vivo (balb/c mouse); Q868H1_LEIME; . References: 15554964 16407198 16596344
viability (PATO:0000169) decreased (PATO:0000468) single cell organism (CARO:0000064) amastigote (BTO:0000062) host (GO:0018995) Leishmania mexicana No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: overexpression of ICP generated without affecting growth or differentiation, but reducing virulence in vivo (balb/c mouse); Q868H1_LEIME; . References: 15554964 16407198 16596344
viability (PATO:0000169) decreased (PATO:0000468) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from over expression (ECO:0000120) Leishmania mexicana No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: overexpression of ICP generated without affecting growth or differentiation, but reducing virulence in vivo (balb/c mouse); Q868H1_LEIME; . References: 15554964 16407198 16596344
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania donovani 0   6693   81384   236103   327961   376038   543486   543487   575389   575390   575391   576750  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 22386-37-4; Drug: 36677-78-8; Drug: 52090-11-6; Drug: 98319-30-3; Drug: 300670-24-0; Drug: 302939-54-4; Drug: 303216-44-6; Drug: 309742-24-3; Drug: 312280-89-0; Drug: 315703-20-9; Drug: 320369-30-0; Drug: 322409-94-9; Drug: 330220-86-5; Drug: 335206-77-4; Drug: 347910-28-5; Drug: 352560-86-2; Drug: 363180-61-4; Drug: 413580-11-7; Drug: 416878-80-3; Drug: 419547-26-5; Drug: 428852-79-3; Drug: 825612-08-6; Drug: 825612-09-7; Drug: 825612-10-0. in silico virtual screening of falcipains lead to bioactive compounds against Leishmania promastigotes; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 15588096
catalytic activity (GO:0003824) decreased (PATO:0000468) in vitro (MI:0492) inferred from in-silico analysis (ECO:0000043) Leishmania donovani 0   6693   81384   236103   327961   376038   543486   543487   575389   575390   575391   576750  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 22386-37-4; Drug: 36677-78-8; Drug: 52090-11-6; Drug: 98319-30-3; Drug: 300670-24-0; Drug: 302939-54-4; Drug: 303216-44-6; Drug: 309742-24-3; Drug: 312280-89-0; Drug: 315703-20-9; Drug: 320369-30-0; Drug: 322409-94-9; Drug: 330220-86-5; Drug: 335206-77-4; Drug: 347910-28-5; Drug: 352560-86-2; Drug: 363180-61-4; Drug: 413580-11-7; Drug: 416878-80-3; Drug: 419547-26-5; Drug: 428852-79-3; Drug: 825612-08-6; Drug: 825612-09-7; Drug: 825612-10-0. in silico virtual screening of falcipains lead to bioactive compounds against cysteine protease in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 15588096
catalytic activity (GO:0003824) decreased (PATO:0000468) in vitro (MI:0492) inferred from specific protein inhibition (ECO:0000020) Leishmania donovani 0   6693   81384   236103   327961   376038   543486   543487   575389   575390   575391   576750  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 22386-37-4; Drug: 36677-78-8; Drug: 52090-11-6; Drug: 98319-30-3; Drug: 300670-24-0; Drug: 302939-54-4; Drug: 303216-44-6; Drug: 309742-24-3; Drug: 312280-89-0; Drug: 315703-20-9; Drug: 320369-30-0; Drug: 322409-94-9; Drug: 330220-86-5; Drug: 335206-77-4; Drug: 347910-28-5; Drug: 352560-86-2; Drug: 363180-61-4; Drug: 413580-11-7; Drug: 416878-80-3; Drug: 419547-26-5; Drug: 428852-79-3; Drug: 825612-08-6; Drug: 825612-09-7; Drug: 825612-10-0. in silico virtual screening of falcipains lead to bioactive compounds against cysteine protease in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 15588096
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania donovani No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 2935-91-3; Drug: 24117-97-3; Drug: 98647-23-5; Drug: 198124-18-4; Drug: 256238-87-6; Drug: 257287-52-8; Drug: 263157-80-8; Drug: 294854-43-6; Drug: 303124-84-7; Drug: 303147-38-8; Drug: 321579-84-4; Drug: 331247-87-1; Drug: 337923-53-2; Drug: 338791-39-2; Drug: 675828-74-7; Drug: 676226-56-5; Drug: 678967-57-2; Drug: 681213-40-1; Drug: 686272-33-3; Drug: 696586-43-3; Drug: 705250-31-3; Drug: 708987-83-1; Drug: 831234-40-3; Drug: 882161-95-7; Drug: 882161-98-0; Drug: 882161-99-1; Drug: 882162-00-7; Drug: 882162-01-8; Drug: 882162-02-9; Drug: 882162-03-0; Drug: 882162-04-1; Drug: 882162-05-2; Drug: 882162-06-3; Drug: 882162-07-4; Drug: 882162-08-5; Drug: 882162-09-6; Drug: 882162-10-9; Drug: 882162-11-0; Drug: 882162-12-1; Drug: 882162-13-2; Drug: 882162-14-3. in silico virtual screening of falcipains lead to bioactive compounds against Leishmania promastigotes; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 16509575
catalytic activity (GO:0003824) decreased (PATO:0000468) in vitro (MI:0492) inferred from in-silico analysis (ECO:0000043) Leishmania donovani No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 2935-91-3; Drug: 24117-97-3; Drug: 98647-23-5; Drug: 198124-18-4; Drug: 256238-87-6; Drug: 257287-52-8; Drug: 263157-80-8; Drug: 294854-43-6; Drug: 303124-84-7; Drug: 303147-38-8; Drug: 321579-84-4; Drug: 331247-87-1; Drug: 337923-53-2; Drug: 338791-39-2; Drug: 675828-74-7; Drug: 676226-56-5; Drug: 678967-57-2; Drug: 681213-40-1; Drug: 686272-33-3; Drug: 696586-43-3; Drug: 705250-31-3; Drug: 708987-83-1; Drug: 831234-40-3; Drug: 882161-95-7; Drug: 882161-98-0; Drug: 882161-99-1; Drug: 882162-00-7; Drug: 882162-01-8; Drug: 882162-02-9; Drug: 882162-03-0; Drug: 882162-04-1; Drug: 882162-05-2; Drug: 882162-06-3; Drug: 882162-07-4; Drug: 882162-08-5; Drug: 882162-09-6; Drug: 882162-10-9; Drug: 882162-11-0; Drug: 882162-12-1; Drug: 882162-13-2; Drug: 882162-14-3. in silico virtual screening of falcipains lead to bioactive compounds against cysteine protease in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 16509575
catalytic activity (GO:0003824) decreased (PATO:0000468) in vitro (MI:0492) inferred from specific protein inhibition (ECO:0000020) Leishmania donovani No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 2935-91-3; Drug: 24117-97-3; Drug: 98647-23-5; Drug: 198124-18-4; Drug: 256238-87-6; Drug: 257287-52-8; Drug: 263157-80-8; Drug: 294854-43-6; Drug: 303124-84-7; Drug: 303147-38-8; Drug: 321579-84-4; Drug: 331247-87-1; Drug: 337923-53-2; Drug: 338791-39-2; Drug: 675828-74-7; Drug: 676226-56-5; Drug: 678967-57-2; Drug: 681213-40-1; Drug: 686272-33-3; Drug: 696586-43-3; Drug: 705250-31-3; Drug: 708987-83-1; Drug: 831234-40-3; Drug: 882161-95-7; Drug: 882161-98-0; Drug: 882161-99-1; Drug: 882162-00-7; Drug: 882162-01-8; Drug: 882162-02-9; Drug: 882162-03-0; Drug: 882162-04-1; Drug: 882162-05-2; Drug: 882162-06-3; Drug: 882162-07-4; Drug: 882162-08-5; Drug: 882162-09-6; Drug: 882162-10-9; Drug: 882162-11-0; Drug: 882162-12-1; Drug: 882162-13-2; Drug: 882162-14-3. in silico virtual screening of falcipains lead to bioactive compounds against cysteine protease in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 16509575
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania major No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 872361-01-8; Drug: 872361-02-9; Drug: 886061-72-9; Drug: 886061-73-0; Drug: 886061-74-1; Drug: 886061-75-2; Drug: 886061-76-3; Drug: 886061-77-4; Drug: 886061-78-5; Drug: 886061-79-6; Drug: 886061-80-9; Drug: 886061-81-0; Drug: 886061-82-1; Drug: 886061-85-4; Drug: 886061-86-5; Drug: 886061-87-6; Drug: 886061-88-7; Drug: 886061-89-8; Drug: 886061-90-1; Drug: 886061-91-2; Drug: 886061-92-3; Drug: 886061-93-4; Drug: 886061-99-0; Drug: 886062-00-6; Drug: 886062-05-1; Drug: 886062-06-2; Drug: 886062-07-3; Drug: 886062-08-4; Drug: 886062-09-5; Drug: 886062-10-8; Drug: 886062-11-9; Drug: 886062-12-0; Drug: 886062-13-1; Drug: 886062-14-2; Drug: 886062-15-3; Drug: 886062-16-4; Drug: 886062-17-5; Drug: 906674-95-1. chemical inhibition with peptidomimetics and Aziridine-2,3-dicarboxylates leads to slow growth of Leishmania sp. in cell assay; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 16801424

In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.

In any case, if you have information about papers containing relevant validation data for this target, please contact us.

Annotated validation

  • Validation: in vivo inhibition
  • annotated by: aaronjr@u.washington.edu.
  • References: 11238649 15172223

Associated compounds / Druggability

Known modulators for this target

Compound Source Reference
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References

Predicted associations

By orthology with druggable targets
Non orthologous druggable targets
By sequence similarity to non orthologous druggable targets
No additional associated druggable targets
Obtained from network model

Ranking Plot

Putative Drugs List

Compound Raw Global Species
0.0274 0.2646 0.2643
0.0262 0.269 0.2674
0.0256 0.2629 0.2643
0.0241 0.2579 0.2531
0.054 0.256 0.2548
0.0254 0.2519 0.2517
0.0536 0.256 0.2548
0.0181 0.2561 0.2517
0.0128 0.2549 0.2517
0.0512 0.256 0.2548
0.054 0.256 0.2548
0.0261 0.2579 0.2531
0.0569 0.256 0.2548
0.0282 0.252 0.2517
0.0512 0.256 0.2548
0.0277 0.2579 0.2531
0.0276 0.2594 0.2594
0.0256 0.269 0.2673
0.0508 0.256 0.2548
0.0255 0.2613 0.2613
0.0243 0.2594 0.2594
0.0536 0.256 0.2548
0.0564 0.256 0.2548
0.0282 0.2697 0.2692
0.0484 0.256 0.2548
0.0233 0.2508 0.2442
0.0265 0.2592 0.2643
0.0249 0.2512 0.2517
0.0277 0.2579 0.2531
0.0244 0.2514 0.2482
0.0234 0.2594 0.2594
0.0251 0.2594 0.2594
0.0227 0.2594 0.2594
0.054 0.256 0.2548
0.0256 0.2594 0.2594
0.0244 0.2681 0.2673
0.0229 0.2594 0.2594
0.023 0.2681 0.2673
0.0247 0.2579 0.2531
0.0227 0.2675 0.2643
0.0279 0.2595 0.2594
0.0277 0.2579 0.2531
0.027 0.258 0.2492
0.0183 0.2741 0.2735
0.0571 0.2578 0.2517
0.0238 0.269 0.2673
0.0181 0.2582 0.2582
0.0265 0.2549 0.2643
0.024 0.269 0.2673
0.0353971 0.305248 0.303626
0.0569 0.256 0.2548
0.0277 0.2646 0.2643
0.0564 0.2578 0.2517
0.0255 0.2542 0.2482
0.0229 0.26 0.2594
0.024 0.251 0.2482
0.0484 0.256 0.2548
0.0246 0.269 0.2673
0.0233 0.2514 0.2482
0.0282 0.2697 0.2692
0.0536 0.256 0.2548
0.0243 0.2579 0.2531
0.0408 0.256 0.2548
0.0232 0.2546 0.2482
0.0682114 0.331076 0.32461
0.0564 0.2549 0.2517
0.0234 0.2594 0.2594
0.0536 0.256 0.2548
0.0231 0.2681 0.2673
0.0235 0.269 0.2673
0.028 0.2646 0.2643
0.0256 0.2579 0.2531
0.0274 0.2579 0.2531
0.0248 0.251 0.2482
0.0569 0.256 0.2548
0.0580982 0.331185 0.32461
0.023 0.2646 0.2643
0.0255 0.2512 0.2527
0.0266 0.2594 0.2594
0.0274 0.2646 0.2643
0.0243 0.2594 0.2594
0.024 0.2579 0.2531
0.0252 0.2519 0.2517
0.0265 0.2592 0.2643
0.0181 0.2582 0.2582
0.0277 0.2695 0.2692
0.0235 0.2594 0.2594
0.0282 0.2697 0.2692
0.0226 0.2594 0.2594
0.0564 0.256 0.2548
0.0255 0.2613 0.2613
0.0580982 0.331185 0.32461
0.0272 0.2645 0.2643
0.0275 0.269 0.2673
0.0236 0.2579 0.2531
0.0512 0.256 0.2548
0.0233 0.2508 0.2442
0.024 0.2579 0.2531
0.028 0.2646 0.2643
0.023 0.2594 0.2594
0.0256 0.2549 0.2517
0.0508 0.256 0.2548
0.0564 0.2578 0.2517
0.0251 0.2594 0.2594
0.0256 0.2579 0.2531
0.0263 0.2511 0.2482
0.0282 0.2641 0.2517
0.0255 0.2613 0.2613
0.0234 0.2594 0.2594
0.0272 0.2646 0.2643
0.0265 0.2649 0.2683
0.023 0.2646 0.2643
0.0271 0.2594 0.2594
0.0229 0.26 0.2594
0.0236 0.26 0.2594
0.0277 0.2695 0.2692
0.0277 0.2695 0.2692
0.0242 0.2673 0.2673
0.0234 0.2594 0.2594
0.0229 0.2519 0.2518
0.0261 0.2612 0.2612
0.0231 0.2681 0.2673

Assayability

Assay information

No assay information for this target.

Reagent availability

  • Lmaj008621AAA;
  • Type Source Notes
    soluble recombinant protein Structural Genomics for Pathogenic Protozoa (SGPP) Lmaj008621; Recombinant protein: full-length; Source: L major; inhibitor of cysteine peptidase ;

Bibliographic References

14 literature references were collected for this gene.

If you have references for this gene, please enter them in a user comment (below) or Contact us.

User comments

No user comments are available for this gene. Log in to add comments, or register.

Enter your comment

User ()
Gene identifier LmjF.24.1770 (Leishmania major), inhibitor of cysteine peptidase
Title for this comment
Comment